Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: A nationwide cohort study

Circulation

Volumn 129, Issue 15, 2014, Pages 1577-1585

  Lamberts, Morten ^a   Gislason, Gunnar H ^a,b   Lip, Gregory Y H ^c   Lassen, Jens Flensted ^d   Olesen, Jonas Bjerring ^a   Mikkelsen, Anders P ^a   Sørensen, Rikke ^a   Køber, Lars ^e   Torp Pedersen, Christian ^f   Hansen, Morten Lock ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e University of Copenhagen   (Denmark)

^f AALBORG UNIVERSITY   (Denmark)

Author keywords

antithrombotic agents; atrial fibrillation; hemorrhage; myocardial infarction; stroke

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PHENPROCOUMON; WARFARIN;

AGED; ARTICLE; BLEEDING DISORDER; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DEATH; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANTITHROMBOTIC AGENTS; ATRIAL FIBRILLATION; HEMORRHAGE; MYOCARDIAL INFARCTION; STROKE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COHORT STUDIES; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHENPROCOUMON; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STROKE; TICLOPIDINE; VITAMIN K; WARFARIN;

EID: 84899072952     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.004834     Document Type: Article

References (33)

1. Camm AJ, Lip G Y, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2012 Focused update of the ESC guidelines for the management of atrial fbrillation: an update of the 2010 ESC guidelines for the management of atrial fbrillation: developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413.
2. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;126:875-910.
3. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Consensus document: antithrombotic therapy in patients with atrial fbrillation undergoing coronary stenting: a North-American perspective. Thromb Haemost. 2011;106:572-584.
4. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F; Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fbrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary: a consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010;31:1311-1318.
5. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE, Køber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fbrillation. Arch Intern Med. 2010;170:1433-1441.
6. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, Madsen JK, Hansen PR, Køber L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-1974.
7. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Køber L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fbrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185-1193.
8. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY; American College of Chest Physicians. Antithrombotic therapy for atrial fbrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl):e531S-e575S.
9. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van 't Hof AW, ten Berg JM; WOEST Study Investigators. Use of clopido-grel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107-1115.
10. Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health. 2011;39(suppl):12-16.
11. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003;56:124-130.
12. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Grønbaek M. Alcohol consumption and risk of atrial fbrillation in men and women: the Copenhagen City Heart Study. Circulation. 2005;112:1736-1742.
13. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology. 2007;28:150-154.
14. Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case defnition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20:560-566.
15. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientifc and Standardization Committee of the International Society on Thrombosis and Haemostasis. Defnition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.
16. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fbrillation with chronic kidney disease. N Engl J Med. 2012;367:625-635.
17. Olesen JB, Lip G Y, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratifcation schemes for predicting stroke and thromboembolism in patients with atrial fbrillation: nationwide cohort study. BMJ. 2011;342:d124.
18. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15:291-303.
19. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither: the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316:1337-1343.
20. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial. Benefts and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent isch-emic Events (CURE) Trial. Circulation. 2004;110:1202-1208.
21. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S; ACTIVE W Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fbrillation in the Atrial fbril-lation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-1912.
22. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-974.
23. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Køber L, Torp-Pedersen C, Hansen ML. Oral anticoagulation and antiplatelets in atrial fbrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981-989.
24. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fbrillation: Virchow's triad revisited. Lancet. 2009;373:155-166.
25. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoag-ulation with warfarin and low-dose aspirin in the primary prevention of isch-aemic heart disease in men at increased risk: the Medical Research Council's General Practice Research Framework. Lancet. 1998;351:233-241.
26. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators. Risks and benefts of combining aspirin with anticoagulant therapy in patients with atrial fbrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fbrillation (SPORTIF) trials. Am Heart J. 2006;152:967-973.
27. Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, Sussex B, Liu L, Guzman R, Cina C, Crowell R, Keltai M, Gosselin G; Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217-227.
28. Cleland JG. Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease. Am J Med. 2012;125:e13
29. Steering committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
30. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical beneft of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a "real world" atrial fbrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107:584-589.
31. Komocsi A, Vorobcsuk A, Kehl D, Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012:1-9.
32. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172:397-402.
33. Steg PG, López-Sendón J, Lopez de Sa E, Goodman SG, Gore JM, Anderson FA Jr, Himbert D, Allegrone J, Van de Werf F; GRACE Investigators. External validity of clinical trials in acute myocardial infarction. Arch Intern Med. 2007;167:68-73.